Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(®) protein MP0250: a preclinical study

The investigational drug MP0250 is a multi-specific DARPin(®) molecule that simultaneously binds and neutralizes VEGF and HGF with high specificity and affinity. Here we studied the antiangiogenic effects of the MP0250 in multiple myeloma (MM). In endothelial cells (EC) isolated from bone marrow (BM...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Luigia, De Veirman, Kim, Giannico, Donato, Saltarella, Ilaria, Desantis, Vanessa, Frassanito, Maria Antonia, Solimando, Antonio Giovanni, Ribatti, Domenico, Prete, Marcella, Harstrick, Andreas, Fiedler, Ulrike, De Raeve, Hendrik, Racanelli, Vito, Vanderkerken, Karin, Vacca, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862584/
https://www.ncbi.nlm.nih.gov/pubmed/29568363
http://dx.doi.org/10.18632/oncotarget.24351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862584/
https://www.ncbi.nlm.nih.gov/pubmed/29568363
http://dx.doi.org/10.18632/oncotarget.24351

Ejemplares similares